Compare Amphastar Pharmaceuticals Inc (AMPH) vs Honest Company Inc (HNST) Price & Performance

AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.

The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.

HNST trades at $4.01, up 1.26% today, with a bullish technical signal from moving averages. The company reported Q1 2026 EPS of $0.01, meeting expectations, but maintains negative net income margins. Cash flow from operations improved to $15.12M in 2025, though revenue declined slightly to $371.32M. Analyst sentiment is mixed with 30% buy ratings.

The outlook remains cautious due to persistent unprofitability and competitive pressures, though cost controls and gross margin expansion offer some upside. Key risks include execution challenges in shifting to retail channels and reliance on wipes & personal care for growth. Investors should weigh improving cash flows against weak bottom-line trends.